BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Australian Diabetes Society - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Australian Diabetes Society
X-ORIGINAL-URL:https://www.diabetessociety.com.au
X-WR-CALDESC:Events for Australian Diabetes Society
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Australia/Melbourne
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20250405T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20251004T160000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20260404T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20261003T160000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20270403T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20271002T160000
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Australia/Melbourne:20260609T000000
DTEND;TZID=Australia/Melbourne:20260609T235959
DTSTAMP:20260601T004113
CREATED:20260522T064142Z
LAST-MODIFIED:20260522T064302Z
UID:10000099-1780963200-1781049599@www.diabetessociety.com.au
SUMMARY:Highlights from American Diabetes Association (ADA) 2026 Scientific Sessions
DESCRIPTION:Join us as we bring you the latest highlights from the American Diabetes Association (ADA) 2026 Scientific Sessions in New Orleans\, LA\, USA\, taking place 5-8 June 2026! \nThe sessions that we will be focusing on: \n\nThe Benefits of Glucagon/GLP-1 Receptor Dual Agonism: Insights from the SYNCHRONIZE™ Phase 3 Studies of Survodutide\nUnlocking the Next Frontier in Treatment of Obesity and Type 2 Diabetes with Retatrutide: A Triple Agonist\, Activating the GIP\, GLP-1 and Glucagon Receptors (TRANSCEND-T2D-1 and TRIUMPH-1 Results)\nREIMAGINE 1\, 2\, 3: Leveraging Amylin and GLP-1 for Type 2 Diabetes Care with CagriSema\nA Phase 2b\, Randomized\, Double-Blind\, Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy\, Safety\, and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus\n\nWe will providing a highlight videos at the end of the conference. Click here to watch the highlight videos as they become available. \nFor any enquiries\, please contact the ADS Secretariat via email to ads@diabetessociety.com.au \n\nThe ADS gratefully acknowledges the support from AstraZeneca\, Boehringer Ingelheim and Lilly.
URL:https://www.diabetessociety.com.au/event/highlights-from-american-diabetes-association-ada-2026-scientific-sessions/
LOCATION:VIC
CATEGORIES:ADS Educational Events,International Meetings,Virtual Event
ATTACH;FMTTYPE=image/png:https://www.diabetessociety.com.au/wp-content/uploads/2026/05/ADS-Event-Highlights_ADA-Jun-2026.png
ORGANIZER;CN="Australian Diabetes Society":MAILTO:admin@diabetessociety.com.au
END:VEVENT
END:VCALENDAR